Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
By John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
By Christoph U. Correll, Richard C. Josiassen, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Management of Late-Life Depression: Focus on Comorbid Conditions
By Warren D. Taylor, MD, and K. Ranga Rama Krishnan, MB, ChB
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Gender-Specific Differences in Depression and Treatment Response
By Susan G. Kornstein, MD, Diane M. E. Sloan, PharmD, and Michael E. Thase, MD
New Advances in the Management of Anxiety Disorders
By Mark H. Pollack, MD
Neurobiology and Mechanisms of Antidepressant Treatment Response in Anxiety
By Philip T. Ninan, MD, Sarah A. Feigon, PhD, and Bettina Knight, RN
Strategies for Treatment-Resistant Depression
By Christos Ballas, MD, Jeffrey P. Staab, MD, MS, and Dwight L. Evans, MD
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
Remission as the Critical Outcome of Depression Treatment
By Michael E. Thase, MD, Diane M. E. Sloan, PharmD, and Susan G. Kornstein, MD